BRPI0714844B8 - molécula de ácido nucleico e seus usos, composição farmaceutica e complexo - Google Patents

molécula de ácido nucleico e seus usos, composição farmaceutica e complexo

Info

Publication number
BRPI0714844B8
BRPI0714844B8 BRPI0714844A BRPI0714844A BRPI0714844B8 BR PI0714844 B8 BRPI0714844 B8 BR PI0714844B8 BR PI0714844 A BRPI0714844 A BR PI0714844A BR PI0714844 A BRPI0714844 A BR PI0714844A BR PI0714844 B8 BRPI0714844 B8 BR PI0714844B8
Authority
BR
Brazil
Prior art keywords
nucleic acid
acid molecule
complex
pharmaceutical composition
type
Prior art date
Application number
BRPI0714844A
Other languages
English (en)
Inventor
Purschke Werner
Jarosch Florian
Eulberg Dirk
Klussmann Sven
Buchner Klaus
Maasch Christian
Dinse Nicole
Original Assignee
Noxxon Pharma Ag
TME Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag, TME Pharma AG filed Critical Noxxon Pharma Ag
Publication of BRPI0714844A2 publication Critical patent/BRPI0714844A2/pt
Publication of BRPI0714844B1 publication Critical patent/BRPI0714844B1/pt
Publication of BRPI0714844B8 publication Critical patent/BRPI0714844B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)

Abstract

MOLÉCULA DE ÁCIDO NUCLEICO, SUA COMPOSIÇÃO FARMACEUTICA, SEUS USOS, SEU COMPLEXO, MÉTODOS DE TRIAGEM, KIT E ANTAGONISTA DE SDF-1. A presente invenção refere-se a uma molécula de ácido nucleico, preferencialmente ligando a SDF-1, selecionada entre o grupo compreendendo moléculas de ácido nucleico tipo A, moléculas de ácido nucleico tipo B, moléculas de ácido nucleico tipo C e moléculas de ácido nucleico tendo uma sequência de ácido nucleico de acordo com qualquer de SEQ. ID. N° 142, SEQ. ID. N° 143 e SEQ. ID. N° 144.
BRPI0714844A 2006-07-18 2007-07-18 molécula de ácido nucleico e seus usos, composição farmaceutica e complexo BRPI0714844B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06014957.2 2006-07-18
EP06014957 2006-07-18
PCT/EP2007/006387 WO2008009437A2 (en) 2006-07-18 2007-07-18 Sdf-i binding nucleic acids

Publications (3)

Publication Number Publication Date
BRPI0714844A2 BRPI0714844A2 (pt) 2013-11-26
BRPI0714844B1 BRPI0714844B1 (pt) 2019-10-01
BRPI0714844B8 true BRPI0714844B8 (pt) 2023-04-18

Family

ID=38947372

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0714844A BRPI0714844B8 (pt) 2006-07-18 2007-07-18 molécula de ácido nucleico e seus usos, composição farmaceutica e complexo

Country Status (17)

Country Link
US (5) US8314223B2 (pt)
EP (1) EP2041282B1 (pt)
JP (1) JP5380287B2 (pt)
KR (2) KR101561652B1 (pt)
CN (2) CN101506364B (pt)
AR (1) AR061929A1 (pt)
AU (1) AU2007276435C1 (pt)
BR (1) BRPI0714844B8 (pt)
CA (1) CA2658267C (pt)
DK (1) DK2041282T3 (pt)
ES (1) ES2663404T3 (pt)
HK (1) HK1131184A1 (pt)
MX (1) MX2009000656A (pt)
PL (1) PL2041282T3 (pt)
PT (1) PT2041282T (pt)
RU (1) RU2590709C2 (pt)
WO (1) WO2008009437A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2663404T3 (es) 2006-07-18 2018-04-12 Noxxon Pharma Ag Ácidos nucleicos de unión a SDF-1
JP5815945B2 (ja) * 2007-08-06 2015-11-17 ノクソン・ファルマ・アクチエンゲゼルシャフト Ｓｄｆ−１結合核酸およびその使用
JP5463621B2 (ja) * 2008-02-27 2014-04-09 ソニー株式会社 標的物質の定量方法
EP2304031A2 (en) * 2008-06-11 2011-04-06 Bionucleon S.r.l. Inhibition of hrp-3 using modified oligonucleotides
TWI578992B (zh) 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
WO2012025251A1 (en) * 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
MX357770B (es) * 2010-09-09 2018-07-24 Noxxon Pharma Ag Star Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer.
JP2014503187A (ja) * 2010-10-29 2014-02-13 ノクソン ファーマ エージー 身体からヘプシジンを除去するためのヘプシジン結合核酸の使用
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
JP2018505144A (ja) * 2014-12-17 2018-02-22 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 抗ｃｘｃｌ１２抗体分子およびその使用
US11221270B2 (en) * 2018-02-27 2022-01-11 Kevan M Evans Method and apparatus for detecting slow leaks
WO2021178923A1 (en) 2020-03-06 2021-09-10 Drinksavvy, Inc. Devices and methods for detecting a target analyte of interest
CN115997122A (zh) 2020-06-26 2023-04-21 拉夸里亚创药株式会社 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物
WO2023154452A1 (en) 2022-02-11 2023-08-17 Waypoint Bio, Inc. Cellular staining probes for analyte detection

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
CA2104698A1 (en) * 1991-02-21 1992-08-22 John J. Toole Aptamers specific for biomolecules and methods of making
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
EP1072273B1 (en) 1998-03-24 2006-07-26 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
US6670149B1 (en) * 1999-03-01 2003-12-30 Millennium Pharmaceuticals, Inc. TWIK-5 potassium channel nucleic acids and uses therefor
US6949243B1 (en) 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
EP1133988A1 (en) 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
WO2002101350A2 (en) 2001-06-07 2002-12-19 Chemocentryx Cell migration assay
GB0225833D0 (en) 2002-11-06 2002-12-11 Univ Leeds Nucleic acid ligands and uses therefor
EP1809303B1 (en) * 2004-09-23 2019-03-06 ARC Medical Devices, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
CN101111598B (zh) * 2004-11-29 2013-03-27 诺松制药股份公司 结合加压素的l-核酸
EP1993584B1 (en) 2006-02-02 2012-05-30 Allergan, Inc. Inhibitors of CXCR4 activity for use in the treatment of ocular disorders
ES2663404T3 (es) 2006-07-18 2018-04-12 Noxxon Pharma Ag Ácidos nucleicos de unión a SDF-1
CA2665239A1 (en) 2006-10-02 2008-05-22 Medarex, Inc. Human antibodies that bind cxcr4 and uses thereof
EP2100140B1 (en) 2006-11-30 2015-05-06 University Of Virginia Patent Foundation Methods for diagnosing fibrotic lung diseases
JP5815945B2 (ja) 2007-08-06 2015-11-17 ノクソン・ファルマ・アクチエンゲゼルシャフト Ｓｄｆ−１結合核酸およびその使用
US20090274687A1 (en) 2008-05-02 2009-11-05 University Of Miami Attenuation of hypoxia induced cardiovascular disorders

Also Published As

Publication number Publication date
AU2007276435A1 (en) 2008-01-24
BRPI0714844A2 (pt) 2013-11-26
CN101506364B (zh) 2013-10-30
AU2007276435B2 (en) 2013-01-24
US20180163207A1 (en) 2018-06-14
CN103555725B (zh) 2017-05-24
MX2009000656A (es) 2009-03-25
DK2041282T3 (en) 2018-04-16
ES2663404T3 (es) 2018-04-12
KR101561652B1 (ko) 2015-10-20
WO2008009437A2 (en) 2008-01-24
RU2009105494A (ru) 2010-08-27
AR061929A1 (es) 2008-10-01
JP5380287B2 (ja) 2014-01-08
US20210139909A1 (en) 2021-05-13
US8314223B2 (en) 2012-11-20
US20150232853A1 (en) 2015-08-20
CA2658267C (en) 2021-03-30
KR20130090428A (ko) 2013-08-13
US9822369B2 (en) 2017-11-21
US20110112172A1 (en) 2011-05-12
HK1131184A1 (en) 2010-01-15
KR20090039717A (ko) 2009-04-22
JP2009543567A (ja) 2009-12-10
US9035038B2 (en) 2015-05-19
AU2007276435C1 (en) 2013-06-13
CN101506364A (zh) 2009-08-12
US20130041019A1 (en) 2013-02-14
CA2658267A1 (en) 2008-01-24
KR101466931B1 (ko) 2014-12-02
WO2008009437A3 (en) 2008-03-27
PT2041282T (pt) 2018-03-13
RU2590709C2 (ru) 2016-07-10
EP2041282B1 (en) 2018-01-03
CN103555725A (zh) 2014-02-05
BRPI0714844B1 (pt) 2019-10-01
EP2041282A2 (en) 2009-04-01
PL2041282T3 (pl) 2018-07-31

Similar Documents

Publication Publication Date Title
BRPI0714844B8 (pt) molécula de ácido nucleico e seus usos, composição farmaceutica e complexo
BRPI0707842B8 (pt) Ácido nucleico capaz de se ligar à mcp-1, seus usos, seu método de detecção, bem como composição farmacêutica, complexo, método para a triagem de um antagonista de quimiocina ou um agonista de quimiocina e kit para a detecção de uma quimiocina
BRPI0616824B8 (pt) peptídeo quimérico, seu uso, composição farmacêutica compreendendo o mesmo, e kit
DK2369005T3 (da) Biologisk aktive proteiner med forøget stabilitet in vivo og/eller in vitro
MX2009009598A (es) Reovirus que tienen secuencias modificadas.
TNSN08064A1 (en) Albumin fusion proteins
CY1116011T1 (el) Hla-a*1101-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση που το περιλαμβανει
EA200870594A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
MX2009002816A (es) Proteinas de fusion de albumina.
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
BRPI0508670A (pt) proteìnas de buganina modificada, citotoxinas e métodos e usos delas
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
WO2007133835A3 (en) Ras mutation and compositions and methods related thereto
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
NI200800193A (es) Anticuerpos humanos anti-il-23, composiciones, métodos y usos.
EP2338333A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MX2008009886A (es) Anticuerpos que enlazan par-2.
AR082502A1 (es) Proteinas osteogenicas de diseño
ATE514714T1 (de) Hutnfr1-selektive antagonisten
BRPI0518042A (pt) polipeptìdeo capaz de se ligar ao fator de necrose de tumor (tnf), ácido nucléico isolado, vetor de expressão, célula hospedeira, método para preparação do referido polipeptìdeo, composição farmacêutica, método de ensaio para detecção de tnf e uso
ATE486127T1 (de) Wiederherstellung der aktivität von 5- enolpyruvylshikimat-3-phosphat-synthase durch fragmentkomplementierung
BRPI0508895A (pt) formas polimorficas e amorfa de {2-flúor-5-[3-((e)-2-piridn-2-il-vinil)-1h-indazol-6-ilamin]- fenil}-amida de ácido 2,5-dimetil-2h-pirazol-3-carboxìlico
DE602005020915D1 (de) Mannose-spezifische adhesinen und deren vervendung

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/07/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: TME PHARMA AKTIENGESELLSCHAFT (DE)